Stephen P. Macmillan - Jul 30, 2024 Form 4 Insider Report for HOLOGIC INC (HOLX)

Role
Chairman, President and CEO, Director
Signature
/s/ Mark W. Irving, attorney-in-fact for Mr. MacMillan
Stock symbol
HOLX
Transactions as of
Jul 30, 2024
Transactions value $
-$2,443,662
Form type
4
Date filed
8/1/2024, 04:09 PM
Previous filing
Jul 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HOLX Common Stock Options Exercise $1.15M +44K +3.8% $26.21 1.2M Jul 30, 2024 Direct F1, F2
transaction HOLX Common Stock Sale -$615K -7.63K -0.64% $80.60 1.19M Jul 30, 2024 Direct F1, F2, F3
transaction HOLX Common Stock Sale -$1.32M -16.2K -1.35% $81.44 1.18M Jul 30, 2024 Direct F1, F2, F4
transaction HOLX Common Stock Sale -$1.67M -20.2K -1.72% $82.32 1.16M Jul 30, 2024 Direct F1, F2, F5
holding HOLX Common Stock 1.15M Jul 30, 2024 MacMillan Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOLX Non-qualified Stock Option (Right to Buy) Options Exercise $0 -44K -100% $0.00* 0 Jul 30, 2024 Common Stock 44K $26.21 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing Rule 10b5-1 trading plan adopted August 30, 2023 to exercise and sell expiring stock options.
F2 Includes 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.
F3 The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $80.00 to $80.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F4 The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $81.00 to $81.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F5 The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $82.00 to $82.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F6 This option to purchase common stock became exercisable in equal installments on each of the first five anniversaries of the grant date, November 7, 2014.